UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancer.
Specific blood markers may predict which hormone therapies will work for advanced prostate cancer, guiding smarter treatment choices.
Using WES of ENZA-resistant versus sensitive cell lines followed by digital droplet PCR validation in mCRPC patient cfDNA, UCA1 copy number gain emerged as a predictive marker for ENZA resistance; AR gain predicted abiraterone resistance. These treatment-specific cfDNA biomarkers could inform therapy selection in mCRPC but require larger prospective validation.
What the study was
- Study design
- Translational biomarker study (cell line WES/transcriptome + clinical cfDNA cohort)
- Population
- Metastatic castration-resistant prostate cancer (mCRPC) patients receiving enzalutamide, abiraterone, or docetaxel
- Sample size
- 80
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Scientific Reports
Why it surfaced
Novel cfDNA biomarker for treatment-specific resistance in mCRPC; small exploratory cohort (n=20 per arm) limits current applicability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.